C&EN Webinars | DMPK strategies in preclinical development of oligonucleotide therapeutics

This webinar provides an overview of DMPK strategies for oligonucleotide therapeutics in preclinical development, covering ASO and siRNA. It highlights their unique ADME properties—including limited oral absorption, rapid tissue uptake into liver and kidney, nuclease-mediated metabolism, and predominantly renal/biliary excretion—as well as the low   direct risk of CYP- or transporter-mediated drug-drug interactions.

The session then outlines practical in vitro and in vivo DMPK approaches, such as cell uptake assays, plasma protein binding methods, metabolism and metabolite ID studies, DDI assessment, tissue distribution using QWBA, and PK/PD correlation with target-tissue concentrations. Case studies on GalNAc-siRNA and multi-platform oligonucleotide PK/PD studies illustrate how to design stage-appropriate   preclinical DMPK studies and support IND-enabling development.

Join this webinar to learn:

• Explain the unique ADME properties of ASO and siRNA

• Select fit-for-purpose in vitro and in vivo DMPK methods

• Evaluate metabolic stability and delivery-system component risks